Pharmaceuticals, Biotechnology and Life Sciences
LONDON–(BUSINESS WIRE)–ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer. Promatix will use its multi-omic proprietary dat…
LONDON–(BUSINESS WIRE)–ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer. Promatix will use its multi-omic proprietary dat…
Experimental PIPAC treatment may extend life for patients with advanced ovarian, uterine, gastric, appendix and colorectal cancers.
NEW HYDE PARK, N.Y.–(BUSINESS WIRE)–Long Island Jewish (LIJ) Medical Center, in collaboration with the Northwell Heal…
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophtha…
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophtha…
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophtha…
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophtha…
New CEO to lead Dreem through its evolution of focusing on the healthcare industry; Hugo Mercier exits the company for new entrepreneurial ventures
PARIS–(BUSINESS WIRE)–Dreem, a sleep technology leader, today announced that Quentin Soulet de Brugiè…
Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evalu…
Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evalu…